← Back to Search

NMDA receptor antagonist

Intranasal Ketamine + Standard Analgesia for Sickle Cell Disease

Phase 3
Waitlist Available
Research Sponsored by Abigail Nixon
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes
Awards & highlights

Study Summary

This trial will study whether intranasal ketamine can help relieve pain for children with sickle cell disease who are in the midst of a vaso-occlusive crisis and are waiting for an IV line to be placed.

Eligible Conditions
  • Sickle Cell Disease
  • Vaso Occlusive Crisis
  • Intranasal Ketamine
  • Pain relief
  • Sickle Cell Crisis
  • Ketamine

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Pain Score Using Numeric Rating Scale (age>11yr)
Change in Pain Score Using Wong Baker/FACES (age<11yr)
Pain
Secondary outcome measures
Additional Opiate Medication
Patient Satisfaction
Rate of Admission
+1 more

Trial Design

2Treatment groups
Active Control
Group I: Intranasal Ketamine + Standard AnalgesiaActive Control1 Intervention
Enrolled patients will receive one dose of Intranasal Ketamine dosed at 1mg/kg (Ketamine 500mg/10 mL solution) after triage while waiting for IV placement (max 50mg).
Group II: Standard AnalgesiaActive Control1 Intervention
Patients receiving "no intervention" will receive no intranasal ketamine while awaiting intravenous line placement for parenteral pain control.

Find a Location

Who is running the clinical trial?

Abigail NixonLead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Intranasal Ketamine For Pain Control In Patients With Sickle Cell Disease And Vaso-occlusive Episode (VOE) In The PED
Abigail Nixon 2020. "Intranasal Ketamine For Pain Control In Patients With Sickle Cell Disease And Vaso-occlusive Episode (VOE) In The PED". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04150757.
All > Sickle Cell Disease > Sickle Cell
~9 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top